Tag: Gilead

Gilead and Galapagos Signed Research and Development Collaboration

Gilead Sciences, Inc. and Galapagos NV announced that they have entered into a 10-year global research and development collaboration. Through this agreement, Gilead will gain access to an innovative p...

Gilead Sciences and IHI Announce Strategic Collaboration

Gilead Sciences, Inc. and the Renown Institute for Health Innovation announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of...

Gilead Sciences Unite with Nurix to Develop Innovative Cancer Drugs

Gilead Sciences, Inc. and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, announced a global strategic collaboration to discove...

AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead

AbCellera, a leader in therapeutic antibody discovery from natural immune systems, announced it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic antibody cand...

Biocartis and Kite in Master Development and Commercialization Agreement

Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced that it has entered into a Master Development and Commercialization Agreement with Kite, a G...

Kite to Expand Cell Therapy Production Capabilities

Kite, a Gilead Company, today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly...

Gilead and insitro Partners in NASH Field

Gilead Sciences Inc. and insitro announced that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH). Un...

Gilead’s Kite and MaxCyte in Multi-Drug Clinical Agreement

MaxCyte, the global cell-based medicines and life sciences company, announced that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial a...

Gilead’s NASH Drug Does not Meet Endpoint in Trial

Gilead Sciences, Inc. have announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, or...

Sales of Gilead Flagship Treatment Fell

Gilead Sciences Inc on Monday reported a fourth-quarter profit that fell short of Wall Street estimates, sending shares lower, as sales of its flagship hepatitis C treatments continued to slide and it...